On Jun. 8, 2020, Evotec announced that its Seattle-based subsidiary Just – Evotec Biologics had entered into an agreement with Advanced BioScience Laboratories (ABL), a global contract development and manufacturing organisation (“CDMO”) to the U.S. Government and biopharmaceutical industry. This project was 100% funded with Federal funds under a $ 318.5 millon contract from the National Institute of Allergy and Infectious Diseases.

Under the agreement, Just – Evotec Biologics will design a highly efficient manufacturing process required for the production of Phase I cGMP clinical supply of a broadly neutralising antibody (“bnAb”) against HIV. Just – Evotec Biologics will support ABL by designing scalable development processes capable of producing a suitably scaled production run under cGMP conditions acceptable for human clinical trials. Under the agreement, Just – Evotec Biologics will also design a product formulation suitable for clinical infusion and provide assay development and release and stability testing services.

No financial terms of the agreement were disclosed.